title: Hallucinogenic and stimulatory amphetamine derivatives: fingerprinting DOM, DOI, DOB, MDMA, and MBDB by spectral analysis of brain field potentials in the freely moving rat (Tele-Stereo-EEG).
abstract: Telemetric recordings of field potentials from frontal cortex, hippocampus, striatum and reticular formation of freely moving rats were analysed before and after injection of the enantiomeric hallucinogenic amphetamine derivatives R-DOB [(-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane], R-DOM [(-)-1-(2,5-dimethoxy-4-methylphenyl)-2-amino-propane] and R-DOI [(-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane] as well as the nonhallucinogenic amphetamine derivatives S-MBDB [(+)-N-methyl-1-(1,3-benzodioxol-5-yl)butanamine] and S-MDMA [(+)-3,4-methylenedioxymethamphetamine] and S-(+)-amphetamine. The frequency analysis of the field potentials revealed a clearcut difference between them. The spectral patterns emerging after injection of the non-hallucinogens were characterized by a general decrease of power, the changes in the alpha2 and delta band being the most prominent, whereas only after the application of the hallucinogenic compounds was a contrasting increase of power observed in the alpha 1 frequency band, especially in the striatum. As increases in alpha 1 power have been correlated in the same pharmacological model to serotonergic control mechanisms, the results are in line with the hypothesis that 5-HT2 receptors, predominantly occurring in the striatum, might be involved in the hallucinogenic action of drugs.
authors.affiliation: Pro Science Private Research Institute GmbH, Linden, Federal Republic of Germany.
authors.forename: W
authors.initials: W
authors.lastname: Dimpfel
authors.forename: M
authors.initials: M
authors.lastname: Spüler
authors.forename: D E
authors.initials: DE
authors.lastname: Nichols
mesh_terms: D004290:DOM 2,5-Dimethoxy-4-Methylamphetamine / Q000031:analogs & derivatives / Q000494:pharmacology; D015104:3,4-Methylenedioxyamphetamine / Q000031:analogs & derivatives / Q000494:pharmacology; D000662:Amphetamines / Q000494:pharmacology*; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000502:physiology*; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D004569:Electroencephalography; D005071:Evoked Potentials / Q000187:drug effects; D006213:Hallucinogens / Q000494:pharmacology*; D007274:Injections, Intraperitoneal; D008297:Male; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D051381:Rats; D011916:Rats, Inbred F344; D013686:Telemetry
chemical_list: D000662:Amphetamines; D000697:Central Nervous System Stimulants; D006213:Hallucinogens; C051570:N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine; D004290:DOM 2,5-Dimethoxy-4-Methylamphetamine; C003943:2,5-dimethoxy-4-bromoamphetamine; D015104:3,4-Methylenedioxyamphetamine; D018817:N-Methyl-3,4-methylenedioxyamphetamine; C015952:4-iodo-2,5-dimethoxyphenylisopropylamine